文献速递妇科

放化疗联合图像引导自适应近距离放疗后子宫切除的经验

Lessons from radiochemotherapy and modern image-guided adaptive brachytherapy followed by hysterectomy.
PubMed 文献 · Gynecol Oncol · 2019-12-18

单中心回顾分析145例局部晚期宫颈癌患者,接受放化疗(RCT)与图像引导自适应近距离放疗(IGABT)后,90例(62.1%)完成子宫切除(HT)。完成HT组与根治性RCT+IGABT组在局部复发、3年LRFS、PRFS及OS上均无显著差异;完成HT组报告了全部4级毒性事件。

要点

  • 完成HT组与未手术组局部复发无显著差异(OR=1.73,p=0.33)。
  • 完成HT组与未手术组3年OS无显著差异(HR=0.81,p=0.65)。
  • ≥2级阴道毒性在根治性RCT+IGABT组更常见(43.6% vs 26.7%,p=0.04)。

核心结论

  • RCT联合IGABT剂量递增后行完成性子宫切除因严重毒性较高似乎并不相容,未见获益且严重晚期并发症增加。
  • 近距离放疗大靶区时联合腔内/组织间插植技术是必需的。

研究设计与样本

  • 单中心回顾性分析145例局部晚期宫颈癌患者,接受RCT与IGABT后,除手术禁忌、腹主动脉旁转移或拒绝手术者外行完成性子宫切除,回顾两组临床结局与并发症。

主要发现

  • 完成HT 90例(62.1%),其中77例(85.6%)为完全组织学反应及镜下病变。
  • 局部复发14例(9.6%),完成HT组与根治性RCT+IGABT组无差异(OR=1.73 [0.57-5.23],p=0.33)。
  • 全人群估计3年LRFS为90% [84%-94%],3年PRFS为93% [87%-96%],两组间无显著差异(HR=0.57 [0.20-1.64],p=0.30;HR=0.37 [0.10-1.31],p=0.12)。
  • 全人群估计3年OS为84% [75%-91%],两组间无显著差异(HR=0.81 [0.32-2.06],p=0.65)。
  • ≥2级阴道毒性在根治性RCT+IGABT组更常见(43.6% vs 26.7%,p=0.04);全部4级毒性事件均报告于完成HT组。

临床怎么用

  • 原文结论提示RCT与IGABT剂量递增后加完成性子宫切除因严重毒性较高似乎并不相容,未见获益且严重晚期并发症增加;大靶区近距离放疗需联合腔内/组织间插植技术。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the clinical outcomes and the safety of radiochemotherapy (RCT) and image-guided adaptive brachytherapy (IGABT) and to evaluate the impact of hysterectomy (HT) as completion of treatment for cervical cancer. METHODS AND MATERIALS: 145 patients with locally advanced cervical cancer were treated at our institution. Patients underwent RCT and IGABT, then hysterectomy (HT) as completion of treatment was performed, with the exception of patients with surgical contraindications, para aortic metastatic disease or patients who refused surgery. Clinical outcomes and morbidity were retrospectively reviewed in both groups. Local relapse free survival (LRFS), pelvic relapse free survival (PRFS) and overall survival (OS) were analyzed. RESULTS: Completion HT was performed in 90 (62.1%) patients. Complete histological response and microscopic disease were found in 77 patients (85.6%). Local relapse was observed in 14 patients (9.6%) without differences between completion HT group and the definitive RCT and IGABT group (Odds Ratio OR = 1.73 [0.57-5.23], p = 0.33). The estimated 3-year LRFS and PRFS for the entire population were respectively 90% [84%-94%] and 93% [87%-96%], with no significant differences between them (respectively Hazard Ratio HR = 0.57 [0.20-1.64], p = 0.30 and HR = 0.37 [0.10-1.31], p = 0.12). The estimated 3-year OS rate for the whole population was 84% [75%-91%] with no significant differences between groups (HR = 0.81 [0.32-2.06], p = 0.65). Regarding morbidity, grade ≥ 2 vaginal toxicity was more frequent in the definitive RCT and IGABT group (43.6% vs 26.7%, p = 0.04). All grade 4 toxicity events were reported in the completion HT group. CONCLUSIONS: Due to high severe toxicity, RCT and IGABT with dose escalation followed by completion hysterectomy don't seem compatible. No benefit and increased severe late morbidity were observed. Combined intracavitary/interstitial technique is mandatory in large target volume at brachytherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Varela Cagetti L, Zemmour C, Minsat M, et al. Lessons from radiochemotherapy and modern image-guided adaptive brachytherapy followed by hysterectomy. Gynecol Oncol. 2019. PMID: 31864683. doi:10.1016/j.ygyno.2019.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。